Received Apr 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | h7rf2 | — |
Twinrix to pediatric patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 12-month-old male patient who received HAB (Twinrix adult) (batch number h7rf2, expiry date 17-JAN-2026) for prophylaxis. On 01-APR-2025, the patient received the 1st dose of Twinrix adult. On 01-APR-2025, an unknown time after receiving Twinrix adult, the patient experienced inappropriate age at vaccine administration (Verbatim: Twinrix to pediatric patient). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 11-APR-2025 Other HCP reported about the administration of Twinrix to a 12 month old male patient, who was given the dose on April 1st, 2025, which led to inappropriate age at vaccine administration. They accepted follow-up.